ArticleFrontiers in medicine2026
Multimodality therapy for stage IB3 cervical cancer with a delayed diagnosis at 21 weeks of gestation: from neoadjuvant chemotherapy to adjuvant chemoradiotherapy-a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational cervical cancer is rare, with an incidence of 1.4-4.6 per 100,000 pregnancies. Managing locally advanced cervical cancer in the second trimester is challenging, requiring a balance between maternal oncological safety and fetal viability. No standardized protocol exists for stage IB3 cervical cancer diagnosed at 21 weeks of gestation. Case presentation: A 27-year-old primigravida at 21 weeks of gestation was diagnosed with stage IB3 cervical squamous cell carcinoma. Initial SCC was 60.15 ng/mL, and MRI was suspicious for stage IIB disease. The patient had no routine prenatal care, and placenta previa on ultrasound contributed to misdiagnosis and delayed recognition. Following multidisciplinary team consultation, she received four cycles of neoadjuvant chemotherapy (nab-paclitaxel 400 mg + cisplatin 140 mg per cycle). Serial SCC showed initial response, a plateau with mild elevation after the third cycle, and a modest decline after the fourth (29.33 ng/mL). At 36 weeks, after dexamethasone for fetal lung maturation, concurrent cesarean section and radical surgery (hysterectomy, lymphadenectomy, ovarian transposition) were performed. A live female neonate (2095g, Apgar 10/10) was delivered. Pathology confirmed moderately differentiated squamous cell carcinoma with intermediate stromal invasion (>1/3 and <2/3) and perineural invasion, without lymphovascular invasion or nodal metastasis. Adjuvant pelvic radiotherapy with concurrent cisplatin and vaginal brachytherapy was given. At last follow-up (June 2026), SCC remained normal with no recurrence, and the child showed normal development. Conclusion: Sequential multimodal therapy-NACT, delayed radical surgery at 36 weeks, and adjuvant chemoradiotherapy-is feasible for stage IB3 cervical cancer in the second trimester. Serial SCC monitoring is a useful biomarker for guiding treatment decisions. This case highlights pitfalls including diagnostic delay, radiological overstaging, and false-negative TCT, emphasizing the need for thorough examination and high suspicion in pregnant patients with atypical bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.